ArticleBritish journal of cancer2019

Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase.

Maitreyee K Jathal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.